



- (51) **International Patent Classification:**
C12N 15/113 (2010.01)
- (21) **International Application Number:**
PCT/US2022/023559
- (22) **International Filing Date:**
05 April 2022 (05.04.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/171,522 06 April 2021 (06.04.2021) US
63/312,808 22 February 2022 (22.02.2022) US
- (71) **Applicant: MAZE THERAPEUTICS, INC.** [US/US];
171 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).
- (72) **Inventors: MEKHOUBAD, Shila;** c/o Maze Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US). **MILLER, Georgiana;** c/o Maze Therapeutics, Inc., 171 Oyster Point Boulevard,

Suite 300, South San Francisco, California 94080 (US). **SALLEE, Nathan;** c/o Maze Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US). **GREEN, Eric;** c/o Maze Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US). **WYATT, David;** 250 King St. Unit 764, South San Francisco, California 94107 (US).

- (74) **Agent: SUN, Eileen, S. et al.;** Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

- (54) **Title:** COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY




FIG. 19A

- (57) **Abstract:** The present disclosure relates to the use of UNC13A cryptic exon splice variant specific inhibitors for methods of reducing expression of a UNC13A cryptic exon splice variant in a cell, reducing phosphorylated TAR-DNA binding protein-43 (TDP-43) in a cell, treating TAR-DNA binding protein-43 (TDP-43) proteinopathy in a subject, or treating a subject has been identified as having a UNC13A mutation in intron 20-21 of UNC13A. Antisense oligonucleotides directed against UNC13A cryptic splice variant are also contemplated.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))